RecruitingEarly Phase 1NCT06149676

A Novel Probiotic-antibiotic Combination to Prevent Recurrent Urinary Tract Infections

Sponsor

Ann & Robert H Lurie Children's Hospital of Chicago

Enrollment

35 participants

Start Date

Feb 2, 2022

Study Type

INTERVENTIONAL

Conditions

Recurrent Uti

Summary

Patients with recurrent UTI were randomized to receive either the probiotic Sacchromyces Boulardii at enrollment, and the intracellularly active Ciprofloxacin with their first UTI episode after enrollment, or they received standard of care treatment.

Eligibility

Min Age: 2 YearsMax Age: 17 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Saccharomyces Boulardii 250 MG [Florastor] for people with recurrent uti. The study is currently recruiting participants at 1 location. People eligible for this study include aged 2 Years to 17 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSaccharomyces Boulardii 250 MG [Florastor]

All patients will get the probiotic to be taken daily. If UTI occurs with a sensitive pathogen, we will treat with ciprofloxacin

Locations(1)

Lurie Children's Hospital

Chicago, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06149676

Related Trials

Intravesical Gentamicin to Prevent Recurrent UTI

NCT063327811 location